Overview
Portfolio
More
Nybc Ventures
Invests in early‑stage therapeutics, medical devices, and technologies advancing blood and cellular therapies to improve patient outcomes.
Portfolio
2+
Employees
5+
Founded
2022
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Nybc Ventures
Invests in early‑stage therapeutics, medical devices, and technologies advancing blood and cellular therapies to improve patient outcomes.
Portfolio
2+
Employees
5+
Founded
2022
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 2 of 2 matched portfolio companies
Veralox Therapeutics is developing small molecule therapeutics that inhibit the 12-Lipoxygenase pathway to treat Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). By targeting this enzyme, the company aims to reduce proinflammatory metabolites that contribute to platelet activation in HIT and enhance insulin production in T1D.
Funding: $24.0M
Rough estimate of the amount of funding raised
NYBC VenturesPappas Capital
NYBC VenturesPappas Capital
Funding: $24.0M
Rough estimate of the amount of funding raised
Vitestro develops an autonomous blood drawing device that utilizes AI-based, ultrasound-guided imaging and robotic needle insertion to automate the entire blood collection process. This technology addresses the shortage of healthcare personnel by increasing the efficiency and availability of blood drawing services in hospitals, allowing patients to receive timely diagnostics on their own schedule.
Funding: $34
Rough estimate of the amount of funding raised
NYBC VenturesSonder Capital
NYBC VenturesSonder Capital
Funding: $34
Rough estimate of the amount of funding raised